Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing global expansion of its insulin titration solution with Novo Nordisk. Initially, the companies successfully commercialized Dose Check, a white-labeled version of iSage RxTM, in select countries in South America. Now, with Amalgam’s recently received CE Mark for iSage Rx and Dose Check, Novo Nordisk is planning a global expansion. In 2021, Dose Check will launch in multiple countries in Europe and Asia.

“We’re excited about expanding our partnership with Amalgam and bolstering our efforts to facilitate evidence-based insulin initiation and titration in conjunction with our strong insulin portfolio. The Dose Check application has been well received by patients and healthcare providers in South America and the launch data is impressive. We have a tremendous opportunity to support patients and healthcare providers across the globe,” said Anne Dorothee Vonmoos, Novo Nordisk’s senior director, head of commercial planning in io-so commercial affairs and strategy.

“The Dose Check program is evidence of Amalgam’s unique capabilities to support life sciences companies from R&D to commercialization. Amalgam now has software as a medical device (SaMD) solutions cleared on three continents. We look forward to expanding the Dose Check program and supporting Novo Nordisk on a global basis,” said Ryan Sysko, chief executive officer and founder of Amalgam Rx.